Lite Strategy, Inc. Revenue from Contract with Customer, Including Assessed Tax
Lite Strategy, Inc. (LITS) reported Revenue from Contract with Customer, Including Assessed Tax of $488.00 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2018-11-08
- Lite Strategy, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-09-30 was $488.00K, a 72.44% increase year-over-year.
- Lite Strategy, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2017-09-30 was $283.00K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month |
|---|---|
| 2018-09-30 | $488.00K 10-Q · filed 2018-11-08 |
| 2017-09-30 | $283.00K 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |